Featured articles
Introducing vivoVerse’s Automated DART Assay: Scalable Developmental and Reproductive Toxicity Testing with C. elegans
January 30, 2026
Developmental and Reproductive Toxicity (DART) Studies Developmental and reproductive toxicity (DART) studies are crucial in identifying risks to human health ...
READ MORE →
vivoVerse revolutionizes developmental toxicity testing with AI-assisted high-throughput C. elegans image analysis
January 15, 2025
Austin, TX — vivoVerse is proud to announce the publication of groundbreaking research that sets a new benchmark for developmental ...
READ MORE →
The FDA’s Shift from Animal Testing: Role of Small Model Organisms as NAMs
April 16, 2025
On April 10, 2025, the FDA announced a major policy shift: creating a roadmap outlining a strategic approach to reduce ...
READ MORE →
NIH Pushes Human-Centered Research; vivoVerse Showcases Organ-on-a-Chip Solutions
May 7, 2025
[Austin, Texas] – The National Institutes of Health (NIH) has announced a major shift in its research priorities, emphasizing ...
READ MORE →
Unlocking the Mysteries of Protein Aggregation: Insights from C. elegans
July 31, 2025
How Dietary and Pharmacological Interventions Can Slow Progression of Neurodegenerative Diseases Protein homeostasis, or proteostasis, is essential for maintaining cellular ...
READ MORE →
More articles
C. elegans scientists awarded 2014 Nobel Prize in Medicine for their pioneering work discovering microRNA
October 28, 2024
The 2024 Nobel Prize in Physiology or Medicine was awarded to Victor Ambros and Gary Ruvkun for the discovery of ...
READ MORE →
vivoVerse awarded NIH/NIEHS grant to develop novel approaches for developmental neurotoxicity testing
July 9, 2024
vivoVerse is excited to announce it has been awarded a Phase I SBIR grant from the National Institute of Environmental ...
READ MORE →
vivoVerse awarded SBIR Phase II grant from the NIEHS
August 5, 2023
vivoVerse (formerly operating as Newormics) is excited to announce it has been awarded a $1.83M Phase II SBIR grant from ...
READ MORE →
vivoVerse cofounders publish single-cell isolation method using femtosecond laser microdissection (fs-LM)
May 3, 2023
vivoVerse cofounders Dr. Adela Ben-Yakar and Dr. Sudip Mondal have published an article in Nature Methods titled “Femtosecond laser microdissection for isolation ...
READ MORE →
vivoVerse at the Society of Toxicology Annual Meeting in Nashville
March 2, 2023
The 2023 Society of Toxicology (SOT) Annual Meeting is coming up this month, and we will be attending! The SOT ...
READ MORE →
vivoVerse moves into new HQ
May 5, 2021
vivoVerse (formerly operating as Newormics) has expanded its base of operations into a customized, newly refurbished space in Austin, Texas. ...
READ MORE →
Newormics resumes operations
August 20, 2020
Dear Colleagues, Customers, and Collaborators: At our Newormics location in Austin, TX, we have been allowed to re-open. We have ...
READ MORE →
vivoVerse Announces Intent to Grant Utility Patent on the vivoChip® by the European Patent Office
August 5, 2020
Patent covers the vivoChip® invention that vivoVerse licensed for use in immobilization of C. elegans for high resolution imaging. AUSTIN, ...
READ MORE →
vivoVerse awarded SBIR Phase II grant from the NIMH
July 8, 2020
vivoVerse (formerly operating as Newormics) is excited to announce it has been awarded a $2.25M Phase II SBIR grant from ...
READ MORE →
COVID-19 UPDATE
March 27, 2020
Dear Customers, Colleagues, and Collaborators: At Newormics, we recognize that combating the spread of this new virus requires a global ...
READ MORE →
